Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes. ・The company plans to launch more than 20 trials in 2026, ...

“Pfizer appears cheap with a near 7% yield, but capital allocation constraints undermine its investment case. Nearly all of ...

Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its ...

According to TipRanks.com, Williams is a 2-star analyst with an average return of 1.6% and a 41.2% success rate. Williams covers the Healthcare sector, focusing on stocks such as Alterity Therapeutics ...

Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly ...

Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

Pfizer is expected to post fourth-quarter adjusted earnings of 57 cents a share on revenue of $16.85 billion, according to analysts polled by FactSet. That compares with adjusted earnings of 63 cents ...

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance (1) provided on December 16, 2025. EXECUTIVE COMMENTARY ...

NEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Tuesday reported a loss of $1.65 billion in its fourth quarter. On a per ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on ...

Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides ...